Ruxolitinib and decitabine before stem cell transplant for AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding two drugs (ruxolitinib and decitabine) to the standard chemotherapy before a stem cell transplant can help prevent leukemia from coming back. It is for people with acute myeloid leukemia who have a suitable donor and are otherwise healthy enough for transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (other than the M3 subtype) and your doctor says a stem cell transplant is right for you.
- You have a stem cell donor available — a matched sibling, a half-matched family member (haploidentical), or a matched unrelated donor.
- You are between 12 and 64 years old.
- Your liver and kidney function are within acceptable limits (liver tests up to 2.5 times normal, kidney function normal).
- No active infections that can't be controlled, and no serious mental health conditions that would make it hard to follow the plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding two medicines (ruxolitinib and chidamide) to a “conditioning regimen” before an allogeneic stem cell transplant improves outcomes for people with high-risk B-cell ALL. It may help prepare the body for transplant and reduce the chance of leukemia coming back.
This trial studies whether adding decitabine plus chemotherapy before a stem cell transplant can better control “minimal residual disease” (very small amounts of leukemia left behind) in certain high-risk acute leukemia types. It may help reduce the chance of the leukemia coming back after transplant.
This trial tests whether two drugs—ruxolitinib (a JAK inhibitor) and azacitidine (a low-dose chemotherapy)—can help prevent acute myeloid leukemia from coming back after you receive a stem cell transplant from an unrelated donor. The transplant uses a gentler conditioning approach to reduce side effects while fighting the cancer.
This trial tests a new drug combination to help people with relapsed or refractory acute myeloid leukemia (AML) get ready for a stem cell transplant. The goal is to make the transplant more effective and improve outcomes.
This trial tests whether a new drug combination (Dec-FB4) works better than an existing one (FB4) as preparation for a stem cell transplant in people with acute myeloid leukemia that is in remission. The goal is to improve outcomes for patients who have a suitable donor.
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.